Elevated plasma miR-210 expression is associated with atypical genitalia in patients with 46,XY differences in sex development

Felipe Martins Elias1 | Mirian Yumi Nishi1 | Maria Helena Palma Sircili1,2 | Rafael Loch Bastista1 | Nathalia Lisboa Gomes1 | Maria Tereza Martins Ferrari1 | Elaine Maria Frade Costa1 | Francisco Tibor Denes2 | Berenice Bilharinho Mendonca1 | Sorahia Domenice1

1Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM-42, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
2Departamento de Urologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Correspondence
Sorahia Domenice, Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM-42, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Eneas de Carvalho Aguiar, 155, PAMB, 2º andar, bloco 6, São Paulo, SP CEP: 05403-900, Brazil.
Email: sorahiad@gmail.com

Funding information
Conselho Nacional de Desenvolvimento Científico e Tecnológico, Grant/ Award Number: 30873/2018-1 and 303002/2016-6; Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant/Award Number: 05/04726-0, 07/512156, 10/51102-0, 2013/02162-8, 2014/50137-5 and 2018/02895-9 (to FME)

Abstract
Background: Differences of sex development (DSD) is a term used for conditions in which the chromosomal, gonadal or phenotypical sex is atypical. 46,XY DSD patients frequently present undervirilized external genitalia. The expression of different miRNAs in many organs of the male genital system has been reported, and these miRNAs have been associated with testicular function and its disorders, but no description has been related to DSD conditions. This study aimed to evaluate the plasma expression of miR-210 in 46,XY DSD patients who presented atypical genitalia at birth.

Methods: Eighteen 46,XY DSD patients who presented atypical genitalia (undescended testis and/or hypospadias, bifid scrotum or micropenis) at birth and 36 male control individuals were selected. Plasma levels of miR-210 and reference miR-23a were measured using RT-qPCR and the data were analysed by the 2^{−ΔΔCt} method.

Results: MiR-210 plasma levels were significantly higher in 46,XY DSD patients with atypical genitalia than in male control subjects (p = 0.0024). A positive association between miR-210 levels and the presence of cryptorchidism and hypospadias (p = 0.0146 and p = 0.0223) was found in these patients. Significantly higher levels of miR-210 were observed in patients with 46,XY DSD and cryptorchidism than in control subjects (p = 0.0118). These results are in agreement with previous literature reports, in which increased levels of miR-210 expression were observed in human testicular tissue from adult males with undescended testes in comparison with samples of descended testes.

Conclusion: Our study showed a positive association between the presence of atypical genitalia and plasma levels of miR-210 expression in the group of patients with 46,XY DSD of unknown aetiology studied. These findings contribute...
1 | INTRODUCTION

Differences of sex development (DSD) is a term used to describe some conditions in which chromosomal, gonadal and/or phenotypical sex development is atypical. Depending on the cause of DSD and when the change during genital development occurs, atypical genitalia may be present at birth. Atypical external genitalia is identified in approximately 1:4500 newborns (Hughes et al., 2006).

Complex interactions between different pathways contribute to the development of normal male external genitalia (Achermann et al., 2015; Mendonca et al., 2009). These pathways include an androgen-independent step and an androgen-dependent step in addition to other endocrine/environmental influences (Hanley & Arlt, 2006; Kim et al., 2006; MacLaughlin & Donahoe, 2004).

It is well known that the lack of or deficient production, secretion or action of male hormones can cause micropenis, abnormal (ventral) placement of the external urethral meatus (hypospadias) and the absence of one or both testicles in the scrotum (cryptorchidism) (Mendonca et al., 2010; Mendonca et al., 2016). These are features that are frequently identified in 46,XY DSD patients. The affected individual can present a spectrum of genital undervirilization signals (Arnhold et al., 2011; Domenice et al., 2016; Lee et al., 2006).

There are varying degrees of external genital atypia ranging from males with a micropenis to females with clitoromegaly. Different degrees of undervirilized external genitalia were observed in affected members of the same 46,XY DSD family, although a single deleterious allelic variant was identified in all the affected members (Batista et al., 2018).

Modulating factors may affect the expression of mutated proteins and might explain the phenotypical variability for the same allelic variant of one DSD gene (Robevska et al., 2018; Wisniewski et al., 2019). These findings provide evidence that other molecular mechanisms of gene expression regulation might participate in the sex determination and differentiation process as a novel cause of 46,XY DSD and/or as a DSD phenotype modulator. The role of epigenetic regulation has already been demonstrated in sex determination in mammals (Haller & Ma, 2019; Miyawaki & Tachibana, 2019).

Although miRNAs have been mostly studied in cancer and monogenic diseases, the role of miRNAs in DSD remains unknown. MiRNAs are small noncoding RNAs (snRNAs) that consist of approximately 20 to 25 nucleotides (Bartel, 2004; Lee & Ambros, 2001). They interact with the 3’UTR segment of mRNAs by base complementarity in a process that involves the RISC protein complex. This process blocks protein translation and inhibits protein expression (Bartel, 2004).

Several miRNAs have been associated with testicular function and its disorders (Duan et al., 2016; Ibarra-Ramirez et al., 2020; Lian et al., 2009; Tang et al., 2018). Lian et al. described that miR-210 was upregulated in the testes of infertile men with maturation arrest (Lian et al., 2009). This same pattern of miR-210 expression was shown in the cryptorchid testes of adult men (Abu-Halima et al., 2014; Duan et al., 2016; Lian et al., 2009; Tang et al., 2018). The current study aimed to evaluate the plasma expression of miR-210 in patients with 46,XY DSD who had atypical genitalia at birth.

2 | METHODOLOGY

2.1 | Control group and 46,XY DSD patients group

This study was approved by the Ethical Committee of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) (CAAE 90497318.0.0000.0068), and written informed consent was obtained from all patients and control individuals or their parents/legal guardians.

2.1.1 | Control group

Blood samples were collected from 36 male control individuals. The control group consisted of two subgroups: (i) 27 healthy male blood donors between 18 and 55 years of age (average age of 30.3 years; SD ± 10.8) from the Pro-Sangue Foundation Blood Center of São Paulo, hereafter referred to as the postpubertal control group, and (ii) nine healthy males between 3 and 12 years old (average age of...
5.7 years, SD±3.1) who underwent postectomy, hereafter referred to as the prepubertal control group. Controls were also subgrouped into age intervals of the following ranges: 1–12, 18–20, 21–30, 31–40 and 41–55 years old.

Upon examination of the external genitalia of the prepubertal control group, a testicular volume <3 ml and Tanner stage 1 were identified in all subjects. All male control individuals, patients, or their legal representatives were asked to fill out a questionnaire on previous diseases, use of drugs or hormonal therapies, and previous genital surgeries. These factors might interfere with the selected miRNA profile and affect the results.

Physical examination of the external genitalia of the postpubertal control individuals was not performed, and no previous or current treatment for urogenital diseases was mentioned in their questionnaire responses. The hormonal profiles of the control individuals were not evaluated.

2.1.2 46,XY DSD patients group

Blood samples were collected from a group of eighteen 46,XY DSD patients regularly attending our service. All patients were born with atypical external genitalia, and all underwent genitoplasty. All participants had a 46,XY karyotype without numerical or structural abnormalities (20 cells analysed), and underwent hormonal and molecular studies (customized panels of candidate DSD genes or whole-exome sequencing) (Table 1). A list of the gene panel used is provided in Appendix Table A1. In our group of patients, 16 out of 18 were classified as of unknown aetiology.

2.2 Subgrouping of the 46,XY DSD patients

2.2.1 Pubertal status

The 46,XY DSD patients were divided into the following subgroups: the postpubertal DSD subgroup, comprising 12 patients (average age of 31.1 years; SD±16), and the prepubertal DSD subgroup, comprising six patients (average age of 3.15 years; SD±2.8). The prepubertal classification was based on a testicular volume of <3 ml, Tanner stage 1, and/or basal testosterone levels of <20 ng/dl. Data from the first evaluation of the external genitalia of the selected patients conducted at the Development Endocrinology Unit of HC-FMUSP were retrospectively collected from medical records/charts (Table 2). All patients underwent genitoplasty, and in those who presented with cryptorchidism, the testes were located in the scrotum or an orchietomy was performed (if it was not possible to correctly position them or if female sex assignment was done).

2.2.2 Atypical genitalia

The 46,XY DSD patients were grouped according to the following criteria (patients can present more than one): (I) testes position into scrotal testes when both testes were found to have descended into the scrotum, or cryptorchidical testes when at least one testicle was found undescended—8 patients presented with descended testes and 10 patients presented with cryptorchidical testes; (II) the presence or absence of hypospadias—16 patients presented with hypospadias (second- or third-degree hypospadias); (III) presence of complete scrotal fusion or bifid scrotum—10 patients presented with fused scrotum and eight patients presented with bifid scrotum; (IV) the length of a stretched flaccid penis: micropenis, which was indicated by a Penile Length (PL) less than 2.5 standard deviations (SD) below the mean for age or stage of sexual development (PL≤−2.5 SD), 10 patients presented with micropenis.

2.3 Blood collection, processing, and storage

Peripheral venous blood was collected in vacutainer serum tubes that were spray-coated with K2EDTA (BD, North Ryde, NSW, Australia). The blood samples were then centrifuged at 2000g, 2500g, and 3000g for 15 min each to avoid haemolysis of red blood cells. The presence of haemolysis in the plasma was evaluated by nanophotometry at a wavelength of 414 nm. Samples were considered haemolysis-free when the absorbance levels remained below 0.2, as described previously by others (Blondal et al., 2013; Kirschner et al., 2011, 2013; Wong et al., 2006).

It is known that haemolysis in plasma may affect the expression of some miRNAs, as described by Kirschner et al. (2011, 2013) and Blondal et al. (2013). There were seven samples from the postpubertal control group and one sample from the prepubertal control group that showed a reddish colouration characteristic of haemolysis and/or absorption values at 414 nm higher than 0.2, and thus, they were excluded from the analysis (initially n = 44, then n = 36). When haemolysis was detected in the patient, they were recalled for a new blood collection. Only one sample out of 46,XY DSD patients (prepubertal group) had to be excluded and was not recollected (initially n = 19, then n = 18).
TABLE 1  Clinical data of 46,XY DSD patients included in the study, their conditions (age, hormonal therapy use), and results from exome or gene candidate panels at the time of the blood sample collection

| Patient | Social sex | Patient age at the sample collection | Medication in use | Consanguinity | Affected family members | Birth weight | Molecular findings | ClinVar: Clinical significance (Landrum et al., 2014) | ClinGen: Polyphen/SiFT (predicted) (Rehm et al., 2015) |
|---------|------------|--------------------------------------|-------------------|---------------|-------------------------|--------------|-------------------|---------------------------------------------------|-----------------------------------------------------|
| 1       | M          | 2y1m                                 | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 2       | M          | 1y11m                                | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 3       | M          | 2y7m                                 | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 4       | M          | 1y10m                                | No                | No            | No                      | SGA          | BMP8B (ENSG00000116985.6) p.Arg116Cys | Not reported | Probably damaging/deleterious                     |
| 5       | M          | 1y9m                                 | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 6       | M          | 8y9m                                 | No                | No            | 1 Sibling               | AGA          | DHX37 (ENSG00000150990.3) p.Ala737Thr | Not reported | Probably damaging/deleterious                     |
| 7       | M          | 17y                                   | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 8       | F          | 33y                                   | Estradiol         | No            | No                      | AGA          | AR (ENSG00000169083), p.Ser343Ser | Not reported | Benign                                              |
| 9       | M          | 24y                                   | No                | No            | No                      | SGA          | AR (ENSG00000169083), p.Glu213Glu | Not reported | Benign                                              |
| 10      | M          | 14y3m                                 | No                | No            | Father and 1 sibling    | AGA          | nsf                | –                                                 | –                                                  |
| 11      | M          | 15y                                   | No                | No            | No                      | SGA          | nsf                | –                                                 | –                                                  |
| 12      | M          | 64y3m                                 | Testo             | No            | No                      | AGA          | NR5A1 (ENSG00000168066.16), c.1139-3C>A | Not reported | Probably damaging/deleterious                     |
| 13      | F          | 34y6m                                 | Estradiol         | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 14      | M          | 15y2m                                 | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 15      | M          | 48y                                   | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |
| 16      | M          | 37y                                   | Testo             | No            | No                      | AGA          | DHX37 (ENSG00000150990.3) p.Leu67Val | Not reported | Probably benign                                      |
| 17      | F          | 40y                                   | Estradiol         | No            | 1 sibling               | AGA          | nsf                | –                                                 | –                                                  |
| 18      | M          | 12y11m                                | No                | No            | No                      | AGA          | nsf                | –                                                 | –                                                  |

Note: Genbank (Clark et al., 2016) gene ID: BMP8B [656], DHX37 [57647], NR5A1 [2516], AR [367].
Abbreviations: APA, appropriate for gestational age; F, female; gcp, gene-candidate panels; M, male; m, months; nsf, no substantial findings; SGA, small for gestational age; Testo, testosterone; wes, whole exome sequencing; y, years.
TABLE 2  External Masculinization Score (EMS) of the 46,XY DSD patients included in this study

| Patient | Scrotum | Score | Penis: Length (SD) | Score | Urethral position | Score | Gonadal position (R/L) | Score | EMS |
|---------|---------|-------|-------------------|-------|-----------------|-------|------------------------|-------|-----|
| 1       | Bifid   | 0     | −1.1              | 3     | Perineal         | 0     | Inguinal/Inguinal       | 1.0/1.0| 5   |
| 2       | Fused   | 3     | 0                 | 3     | Penile           | 1     | Scrotal/Scrotal         | 1.5/1.5| 10  |
| 3       | Fused   | 3     | −1.0              | 3     | Penile           | 1     | Scrotal/Scrotal         | 1.5/1.5| 10  |
| 4       | Bifid   | 0     | −2.5              | 0     | Perineal         | 0     | Scrotal/Inguinal        | 1.5/1.0| 2.5 |
| 5       | Bifid   | 0     | −2.3              | 3     | Perineal         | 0     | Inguinal/Inguinal       | 1.0/1.0| 5   |
| 6       | Fused   | 3     | −3.9              | 0     | Normal           | 3     | Absent/Absent           | 0/0   | 6   |
| 7       | Bifid   | 0     | −2.3              | 3     | Scrotal          | 1     | Scrotal/Scrotal         | 1.5/1.5| 7   |
| 8       | Fused   | 3     | −2.5              | 0     | Perineal         | 0     | Scrotal/Scrotal         | 1.5/1.5| 6   |
| 9       | Bifid   | 0     | −1.7              | 3     | Perineal         | 0     | Inguinal/Inguinal       | 1.0/1.5| 5.5 |
| 10      | Bifid   | 0     | −5.0              | 0     | Perineal         | 0     | Inguinal/Scrotal        | 1.0/1.5| 2.5 |
| 11      | Bifid   | 0     | −3.3              | 0     | Penile           | 1     | Scrotal/Scrotal         | 1.5/1.5| 4.5 |
| 12      | Bifid   | 0     | −3.6              | 0     | Perineal         | 0     | Inguinal/Inguinal       | 1.0/1.0| 2   |
| 13      | Fused   | 3     | −3.4              | 0     | Perineal         | 0     | Inguinal/Inguinal       | 1.0/1.0| 5   |
| 14      | Fused   | 3     | −5.5              | 0     | Penile           | 1     | Scrotal/Scrotal         | 1.5/1.5| 7   |
| 15      | Fused   | 3     | −2.5              | 0     | Perineal         | 0     | Scrotal/Scrotal         | 1.5/1.5| 6   |
| 16      | Fused   | 3     | −2.5              | 0     | Normal           | 3     | Absent/Absent           | 0/0   | 6   |
| 17      | Bifid   | 0     | −2.5              | 0     | Perineal         | 0     | Scrotal/Abdominal       | 1.5/0.5| 2   |
| 18      | Fused   | 3     | −3                | 0     | Perineal         | 0     | Scrotal/Scrotal         | 1.5/1.5| 6   |

Note: SD, standard deviation; R/L, right and left; EMS, external masculinization score as proposed by Ahmed et al. (2000).

FIGURE 1  First, we questioned whether age or pubertal status could influence miR-210 expression. To test this hypothesis controls were sub-grouped by age into intervals (a), showing no statistical difference. Furthermore, controls (b) and 46,XY DSD patients (c) were sub-grouped into prepubertal and postpubertal status, again, showing no statistical difference in miR-210 expression values. RT-qPCR data were analysed by $2^{-\Delta \Delta C_{T}}$ and then transformed by log conversion, the miR-23a was used as a reference. Box and whiskers represent interquartile, minimum and maximum values; grey dots are the average of duplicates (control subjects) or triplicates (46,XY DSD patients); + and dashed lines represent the mean; a.u. = arbitrary units.
All blood samples were processed no more than 6 hours after collection. The plasma was stored at −80°C until RNA extraction and then kept at −80°C for long-term storage.

2.4 | RNA isolation

RNA was extracted from plasma using the MagMAX mirVana Total RNA Isolation Kit (Thermo Fisher, Waltham, Maryland, USA) and quantified with a Qubit 2.0 fluorometer and HS Assay RNA kit (Thermo Fisher). All steps were performed according to the manufacturer’s instructions.

2.5 | Reverse transcription

Reverse transcription was performed using a TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher), and cDNA was quantified with a Qubit 2.0 fluorometer and dsDNA HS Assay Kit (Thermo Fisher). All steps were performed according to the manufacturer’s instructions.

2.6 | Quantitative real-time PCR

RT–qPCR for miR-210 (chr11:568089–568,198, miRbase [Ambros et al., 2003] accession MIR0000286/MIMAT0000267, 66-cugucgugugacacggcug-87) and the reference miR-23a (chr19:13836587–13,836,659, miRBase [Ambros et al., 2003] accession MIR000079/MIMAT000078, 45-aucacauuggcaggauucc-65) was performed using 1 ng of the preamplification reaction product and the TaqMan Advanced miRNA Assay kit (478532_mir/A25576, and 477970_mir/A25576) with Fast-Advanced Master Mix (Thermo Fisher) according to the manufacturer’s instructions. miR-23a was selected as a reference gene based on the study by Blondal et al. (2013), which showed that this miRNA is not affected by haemolysis and has stable expression in plasma samples.

Reactions were carried out in an Agilent Aria-MX Real-Time System (Agilent, Santa Clara, California, USA). Fluorescence thresholds were set to 0.1 for all miRNAs, and all 40 cycles were considered. MiR-23a was selected as the reference gene, and the $2^{-\Delta Ct}$ method was used to compare the expression levels amongst the groups. A plate replicate and triplicate were used to control individuals and patients, respectively. Ct was set to 40 in samples that demonstrated no Cq for miR-210 in control individuals.

2.7 | Statistical analysis

The Anderson–Darling, D’Agostino’s K², Pearson’s chi-square, Kolmogorov-Smirnov, and Shapiro–Wilk tests were used to analyse the distribution of data. Data were transformed using the lognormal distribution by $y = \log(y)$. Group pairs were compared using unpaired Student’s $t$-test (two-tailed) or the Mann–Whitney test. The $F$ test was used to compare variances. To compare 3 or more groups, ANOVA was used with Tukey’s posttest, or Kruskal–Wallis test with Dunn’s posttest was used. Bartlett’s test was used to compare variances. The results were considered statistically significant when $p < 0.05$.

3 | RESULTS

First, we examined the expression data to identify any differences between miR-210 in prepubertal and postpubertal subgroups. MiR-210 expression was similar in all groups, with a discrete elevation in the “40–55 years” subgroup. Interestingly, no significant differences in plasma miR-210 expression levels were observed in any of the subgroups of the control subjects at different ages (Figure 1a).

Additionally, no significant difference was observed when control individuals were compared according to their pubertal status (prepubertal vs. postpubertal control groups) (Figure 1b). Comparison between the prepubertal and postpubertal 46,XY DSD patient groups also showed no difference in miR-210 expression levels (Figure 1c).

These findings support that the data from both the prepubertal and postpubertal groups could be analysed in conjunction.

Following such findings, the expression levels of plasma miR-210 were significantly higher in the 46,XY DSD patient group than in the control group (Figure 2a). Patients were then grouped according to the features of the External Masculinization Score (EMS), as described by Ahmed et al. (2000). We then sought to analyse the expression values of miR-210 in 46,XY patients by subgroups as described earlier.

A positive association between miR-210 levels and the presence of cryptorchidism was found, and significantly higher levels of miR-210 were observed in 46,XY DSD patients with cryptorchidism than in control subjects (Figure 2b). No significant difference was observed between 46,XY DSD patients with descended testis and control subjects.

Furthermore, 46,XY DSD patients with hypospadias showed significantly higher miR-210 expression
compared with control subjects (Figure 2c). In this case, however, just two patients out of the initial 18 included in the study did not present with hypospadias. Therefore, we could not evaluate its significance against control individuals or 46,XY DSD patients with hypospadias.

Moreover, higher miR-210 expression values were observed in patients with bifid scrotum compared to...
control subjects (Figure 2d). No significant difference was observed when comparing patients presenting with fused scrotums and control individuals. Patients with a micropenis (PL $\leq -2.5$ SD subgroup) showed significantly higher miR-210 levels than control subjects, but no significant difference was observed between individuals in the PL $> -2.5$ SD subgroup and control subjects (Figure 2e).

Three patients were treated with oestradiol, and two patients were under testosterone treatment (Table 1). To determine whether oestradiol or testosterone could alter the miR-210 expression, a heatmap was constructed based on individual miR-210 levels against the mean of control subjects. No association was observed (Figure 2f). Furthermore, only two 46,XY DSD patients, showed lower levels of miR-210 than the mean expression levels of the control group. Two 46,XY DSD patients showed no difference, and fourteen 46,XY DSD patients had higher levels of miR-210 expression than the mean expression levels of the control group. These findings suggest that posttranscriptional mechanisms could play a role in regulating external genitalia development.

4 | DISCUSSION

Over the past years, miRNAs have been shown to influence numerous biological processes and have been associated with different disorders in humans (Mitchell et al., 2008; Saliminejad et al., 2019; Wang, 2017). The role of miRNAs in regulating primordial germ cell specification, spermatogenesis, oogenesis and gonadal tumorigenesis has been widely demonstrated (Panneerdoss et al., 2012; Robles et al., 2019). However, at present, their potential role in 46,XY DSD has rarely been discussed (Ibarra-Ramírez et al., 2020; Wisniewski et al., 2019).

Differential expression of several miRNAs linked to male reproductive disorders has been described, and miR-210 is included in this group (Robles et al., 2019). MiR-210 is ubiquitously expressed in a wide range of cells and has physiological roles in the inhibition of cell proliferation, inhibition of mitochondrial respiration, inhibition of DNA repair, vascular biology and angiogenesis. It is also known to be a major hypoxia-inducible miRNA (Zhang et al., 2012).

Placental hypertension and preeclampsia can lead to foetal hypoxia and affect newborns (Redman & Staff, 2015). A meta-analysis concluded that maternal hypertension diseases, including preeclampsia, were positively associated with hypospadias in human offspring (Sheriff et al., 2019). Moreover, Gunel et al. (2011) found that the expression of miR-210 was increased in the placentas and plasma samples of preeclamptic patients, and it could be detected prenatally with non-invasive methods.

In our study, patients #4 and #9 were considered small for gestational age (Table 1). This reduced foetal growth is a common finding that reaches one-third of infants of mothers with preeclampsia and may explain these patients’ findings (Redman & Staff, 2015). Both patients #4 and #9 showed miR-210 expression values that were higher than the mean of the control individuals.

Previous studies have shown that miR-210 expression is upregulated in the testes of infertile men with maturation arrest (Barbu et al., 2021; Lian et al., 2009). The authors showed that IGF2 (GenBank gene ID: 3481) was directly targeted by miR-210 using in vitro experiments in NT2 cells. Therefore, these data indicated that miR-210 might be associated with spermatogenesis by targeting IGF2 in male infertility (Tang et al., 2018). The effects of the insulin-like growth factor system on testicular differentiation and function are well established (Cannarella et al., 2018; Pitetti et al., 2013). Insulin/IGF signalling is central in the regulation of the final number of Sertoli cells, testicular volume and sperm concentration (Pitetti et al., 2013).

Upregulated miR-210 expression was also demonstrated in human cryptorchid testis and mouse testis subjected to experimental cryptorchidism (Duan et al., 2016). Analyses of human postcryptorchidopexy testicular tissue revealed 297 downregulated and 153 upregulated miRNAs compared with normal testicular tissue, but miR-210 expression was not significantly altered in these samples (Tang et al., 2018). The authors associated the difference in miRNA profiles with the different types of human cryptorchid tissue analysed.

Interestingly, a recent systematic review by Jia and Hao (2021), which analysed dysregulated miRNAs in cryptorchidism, showed 21 potential miRNAs from the studies collected, but only miR-210, miR-449a, and miR-34c were dysregulated in both animal and human tissues from the 185 samples analysed.

Cryptorchidism is a common anomaly in the male genitalia (2% to 4% of male infants) and is frequently observed in 46,XY DSD patients (Barthold & González, 2003; Kalfa et al., 2019). In our group of 46,XY DSD patients with unknown aetiology and atypical genitalia, undescended testes was present in 60% of these patients. The expression of miR-210 in plasma was significantly higher in the DSD group than in the male control group.

Genetic variants were found in patients #4 and #16, but at this time it was not possible to fully clarify their aetiology based on those findings (Table 1), both patients had atypical genitalia, including inguinal (patient #4), and undescended testes (patient #16), and showed higher levels of miR-210 than the mean of controls. Patients #6 (da
Silva et al., 2019) and #12 (Gomes et al., 2022) had their aetiology clarified based on molecular studies (Table 1), and showed higher levels of miR-210 than the mean of controls, the same pattern observed in the group of patients (n = 16), whom besides molecular studies, were still classified as of unknown aetiology. These novel findings may help to clarify the phenotype of 46,XY DSD patients of unknown aetiology.

In addition, the real-time qPCR analysis revealed that our group of 46,XY DSD patients with undescended testis had higher levels of circulating miR-210 than male control individuals, which is in contrast to the 46,XY DSD patients with descended testis. Our results in these plasma samples are in accordance with the findings of Duan et al. (2016) in testicular samples. Unfortunately, testicular tissue samples from DSD patients were not available in our study, preventing the comparison between the expression profile of miR-210 in plasma and undescended testis tissue in DSD patients.

Our study showed a positive association between miR-210 expression and the presence of cryptorchidism and hypospadias, which are two characteristics frequently observed in the atypical genitalia of patients with 46,XY DSD. Deregulation of miR-210 expression might represent a secondary effect of a physiological pathway disorder or a novel aetiological factor in abnormal male sex development.

Findings in this small group of patients had strong statistical values, however further analysis in a large number of 46,XY DSD patients will be necessary to establish the role of miR-210 in their phenotype modulation, and deeper investigation must be done to establish the pathogenic potential of miRNA in 46,XY DSD.

5 | CONCLUSION

The present study showed a positive association between the presence of atypical genitalia and plasma levels of miR-210 expression in the group of patients with 46,XY DSD studied. Our findings contribute to opening a novel perspective on the possible role of miRNAs in the development of the male external genitalia and the broad spectrum of phenotypes presented by patients with 46,XY DSD, more importantly to those that besides molecular studies remain with unknown aetiology.

AUTHOR CONTRIBUTIONS

Designed the research: Elias FM, Mendonca BB, and Domenice S. Performed the research: Elias FM and Nishi FT, Mendonca BB, and Domenice S. Wrote the paper: Elias FM, and Domenice S.

ACKNOWLEDGMENTS

This work has been supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grants No. 308873/2018-1 (to Sorahia Domenice), and No. 303002/2016-6 (to Berenice Bilharinho Mendonca), and by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Grants No. 05/04726-0, 07/512156, 10/51102-0, 2013/02162-8, 2014/50137-5 (to Berenice Bilharinho Mendonca), and No. 2018/02895-9 (to Felipe Martins Elias).

CONFLICT OF INTEREST

The authors declare that they have no competing financial interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

This study was approved by the Ethical Committee of the Hospital das Clínicas of the University of Sao Paulo Medical School, University of Sao Paulo (CAAE 90497318.0.0000.0068), and written informed consent was obtained from all patients and control individuals or their parents/legal guardians.

ORCID

Felipe Martins Elias https://orcid.org/0000-0003-3739-4755
Mirian Yumi Nishi https://orcid.org/0000-0001-6603-3188
Rafael Loch Bastista https://orcid.org/0000-0002-5461-0301
Sorahia Domenice https://orcid.org/0000-0002-4883-7630

REFERENCES

Abu-Halima, M., Backes, C., Leidinger, P., Keller, A., Lubbad, A. M., Hammadeh, M., & Meese, E. (2014). MicroRNA expression profiles in human testicular tissues of infertile men with different histopathologic patterns. *Fertility and Sterility, 101*(1), 78–86. e72. https://doi.org/10.1016/j.fertnstert.2013.09.009

Achermann, J. C., Domenice, S., Bachega, T. A., Nishi, M. Y., & Mendonca, B. B. (2015). Disorders of sex development: Effect of molecular diagnostics. *Nature Reviews. Endocrinology, 11*(8), 478–488. https://doi.org/10.1038/rendo.2015.69

Ahmed, S. F., Khwaja, O., & Hughes, I. A. (2000). The role of a clinical score in the assessment of ambiguous genitalia. *BJU International, 85*(1), 120–124. https://doi.org/10.1046/j.1444-410x.2000.00354.x
Ambros, V., Bartel, B., Bartel, D. P., Burge, C. B., Carrington, J. C., Chen, X., Dreyfuss, G., Eddy, S. R., Griffiths-Jones, S., Marshall, M., Matzke, M., Ruvkun, G., & Tuschl, T. (2003). A uniform system for microRNA annotation. RNA, 9(3), 277–279. https://doi.org/10.1261/rna.2183803

Arnhold, I. J., Melo, K., Costa, E. M., Danilovic, D., Inacio, M., Domenice, S., & Mendonca, B. B. (2011). 46,XY disorders of sex development (46,XY DSD) due to androgen receptor defects: Androgen insensitivity syndrome. Advances in Experimental Medicine and Biology, 707, 59–61. https://doi.org/10.1007/978-1-4419-8002-1_14

Barbu, M. G., Thompson, D. C., Suciu, N., Voinea, S. C., Crestoiu, D., & Predescu, D. V. (2021). The roles of MicroRNAs in male infertility. International Journal of Molecular Sciences, 22(6), 2910. https://doi.org/10.3390/ijms22062910

Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.

Barthold, J. S., & González, R. (2003). The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. The Journal of Urology, 170(6 Pt 1), 2396–2401. https://doi.org/10.1097/01.ju.0000095793.04232.d8

Batista, R. L., Costa, E. M. F., Mendonca, B. B., & Domenice, S. (2011). 46,XY disorders of sex development (46,XY DSD) due to androgen receptor defects: Androgen insensitivity syndrome: A review. Archives of Endocrinology and Metabolism, 62(2), 227–235. https://doi.org/10.20945/2359-3997-00000031

Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang Telium, M., & Dahlsvæn, I. K. (2013). Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods, 59(1), S1–S6. https://doi.org/10.1016/j.ymeth.2012.09.015

Cannarella, R., Condorelli, R. A., La Vignera, S., & Calogero, A. E. (2018). Effects of the insulin-like growth factor system on testicular differentiation and function: A review of the literature. Andrology, 6(1), 3–9. https://doi.org/10.1111/andr.12444

Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J., & Sayers, E. W. (2016). GenBank. Nucleic Acids Research, 44(D1), D67–D72. https://doi.org/10.1093/nar/gkv1276

da Silva, T. E., Gomes, N. L., Lerário, A. M., Keegan, C. E., Nishi, M. Y., Carvalho, F. M., Vilain, E., Barsegian, H., Martinez-Aguayo, A., Forclaz, M. V., Papazian, R., Pedroso de Paula, L. C., Costa, E. C., Carvalho, L. R., Jorge, A. A. L., Elia, F. M., Mitchell, R., Costa, E. M. F., Mendonca, B. B., & Domenice, S. (2019). Genetic evidence of the association of DEAH-Box helicase 37 defects with 46,XY gonadal dysgenesis spectrum. The Journal of Clinical Endocrinology and Metabolism, 104(12), 5923–5934. https://doi.org/10.1210/jc.2019-00984

Domenice, S., Machado, A. Z., Ferreira, F. M., Ferraz-de-Souza, B., Lerário, A. M., Lin, L., Nishi, M. Y., Gomes, N. L., da Silva, T. E., Silva, R. B., Correa, R. V., Montenegro, L. R., Narciso, A., Costa, E. M., Achermann, J. C., & Mendonca, B. B. (2016). Wide spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. Birth Defects Research. Part C, Embryo Today, 108(4), 309–320. https://doi.org/10.1002/bdr2.21145

Duan, Z., Huang, H., & Sun, F. (2016). The functional and predictive roles of miR-210 in cryptorchidism. Scientific Reports, 6, 32265. https://doi.org/10.1038/srep32265

Gomes, N. L., Batista, R. L., Nishi, M. Y., Lerário, A. M., Silva, T. E., de Moraes Narcizo, A., Benedetti, A. F. F., de Assis Funari, M. F., Faria Junior, J. A., Moraes, D. R., Quintão, L. M. L., Montenegro, L. R., Ferrari, M. T. M., Jorge, A. A., Arnhold, I. J. P., Costa, E. M. F., Domenice, S., & Mendonca, B. B. (2022). Contribution of Clinical and genetic approaches for diagnosing 209 index cases with 46,XY differences of sex development. The Journal of Clinical Endocrinology and Metabolism, 107(5), e1797–e1806. https://doi.org/10.1210/clinmn/dgac064

Gunel, T., Zeybek, Y. G., Akçakay, P., Kallelıoğlu, I., Benian, A., Ermiş, H., & Aydınlu, K. (2011). Serum microRNA expression in pregnancies with preeclampsia. Genetik and Molecular Research, 10(4), 4034–4040. https://doi.org/10.4238/2011.November.8.5

Haller, M., & Ma, L. (2019). Temporal, spatial, and genetic regulation of external genitalia development. Differentiation, 110, 1–7. https://doi.org/10.1016/j.diff.2019.08.003

Hanley, N. A., & Arlt, W. (2006). The human fetal adrenal cortex and the window of sexual differentiation. Trends in Endocrinology and Metabolism, 17(10), 391–397. https://doi.org/10.1016/j.tem.2006.10.001

Hughes, I. A., Houk, C., Ahmed, S. F., Lee, P. A., & Consensus Statement on Management of Intersex Disorders. (2006). Consensus statement on management of intersex disorders. Journal of Pediatric Urology, 2(3), 148–162. https://doi.org/10.1016/j.jspuro.2006.03.004

Ibarra-Ramírez, M., Calvo-Anguiano, G., Lugo-Trame, J. J., Martínez-de-Villarreal, L. E., Rodríguez-Torres, D., Nistal, M., & Gonzáles-Peramato, P. (2020). Expression profile of microRNAs in the testes of patients with Klinefelter syndrome. Scientific Reports, 10(1), 11470. https://doi.org/10.1038/s41598-020-68294-7

Jia, H., & Hao, C. (2021). Exploring deregulated miRNAs in cryptorchidism: A systematic review. The Journal of International Medical Research, 49(3), 30060521999950. https://doi.org/10.1177/03000605219999950

Kalifa, N., Gaspari, L., Ollivier, M., Philibert, P., Bergougoux, A., Paris, F., & Sultán, C. (2019). Molecular genetics of hypospadias and cryptorchidism recent developments. Clinical Genetics, 95(1), 122–131. https://doi.org/10.1111/cge.13432

Kim, Y., Kobayashi, A., Sekido, R., DiNapoli, L., Brennan, J., Chabossiers, M. C., Poulat, F., Behringer, R. R., Lovell-Badge, R., & Capel, B. (2006). Fgf9 and Wnt4 act as antagonistic signals to regulate mammalian sex determination. PLoS Biology, 4(6), e187. https://doi.org/10.1371/journal.pbio.0040187

Kirschner, M. B., Edelman, J. J., Kao, S. C., Valley, M. P., van Zandwijk, N., & Reid, G. (2013). The impact of hemolysis on cell-free microRNA Biomarkers. Frontiers in genetics, 4, 94. https://doi.org/10.3389/fgene.2013.00094

Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Valley, M. P., van Zandwijk, N., & Reid, G. (2011). Haemolysis during sample preparation alters microRNA content of plasma. PloS one, 6(9), e24145. https://doi.org/10.1371/journal.pone.0024145

Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M., & Maglott, D. R. (2014). ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Research, 42(Database issue), D980–D985. https://doi.org/10.1093/nar/gkt1113

Lee, P. A., Houk, C. P., Ahmed, S. F., Hughes, I. A., & International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. (2006). Consensus statement on relationships among sequence variation and human phenotype.
management of intersex disorders. International Consensus Conference on Intersex. Pediatrics, 118(2), e488–e500. https://doi.org/10.1542/peds.2006-0738

Lee, R. C., & Ambros, V. (2001). An extensive class of small RNAs in Caenorhabditis elegans. Science, 294(5543), 862–864. https://doi.org/10.1126/science.1065329

Lian, J., Zhang, X., Tian, H., Liang, N., Wang, Y., Liang, C., Li, X., & Sun, F. (2009). Altered miRNA expression in patients with non-obstructive azoospermia. Reproductive Biology and Endocrinology, 7, 13. https://doi.org/10.1186/1477-7827-7-13

MacLaughlin, D. T., & Donahoe, P. K. (2004). Sex determination and differentiation. The New England Journal of Medicine, 350(4), 367–378. https://doi.org/10.1056/NEJMra022784

Mendonca, B. B., Batista, R. L., Domenic, S., Costa, E. M., Arnhold, I. J., Pitetti, J. L., Calvel, P., Zimmermann, C., Conne, B., Papaioannou, V. E., Nigro, L., Aksoy, B., & Nef, S. (2013). Androgen-responsive miRNAs in mouse Sertoli cells. Proceedings of the National Academy of Sciences of the United States of America, 110(5), 10513–10518. https://doi.org/10.1073/pnas.1217454110

Eliaš, F. M., Nishi, M. Y., Sirçili, M. H. P., Bastista, R. L., Gomes, N. L., Ferrari, M. T. M., Costa, E. M. F., Denes, F. T., Mendonca, B. B., & Domenic, S. (2022). Elevated plasma miR-210 expression is associated with atypical genitalia in patients with 46,XY differences in sex development. Molecular Genetics & Genomic Medicine, 10, e2084. https://doi.org/10.1002/mgg3.2084
### APPENDIX

**Table A1** Gene candidate panel

| Genes                  | candidate panel |
|------------------------|-----------------|
| AGTBD7                 | ACVR1B          |
| ARX                    | BBS1            |
| BMP15                  | BMP8B           |
| CYP11A1                | CYP12A1         |
| DND1                   | ESR1            |
| FST                    | GADD45G         |
| HNF1B                  | HPGD            |
| KATNBL1                | LEF1            |
| NANOS3                 | NCOA2           |
| POR                    | PRKACG          |
| SOX10                  | SOX13           |
| SUPT3H                 | TCF21           |

a. AgilentSure Design 2.0 Software (Agilent Technologies), Illumina platform (Illumina Technologies).